Goldman Sachs initiated coverage of Bausch + Lomb (BLCO) with a Neutral rating and $16 price target The firm believes the stock’s current valuation current balances its improving fundamentals and elevated leverage profile and low float.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb to Announce Q3 2025 Results and Host Investor Day
- Bausch + Lomb’s enVista Envy IOL Achieves Key Milestones in Clinical Trial
- Bausch + Lomb publishes enVista Envy trial results
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Bausch + Lomb’s XIIDRA Shows Promising Results for Contact Lens Wearers